Table 2.

Effects of chronic GSK2181236A or BAY 60-4552 treatment on echocardiographic parameters in SHR-SP.

			HSFD + GSK2181236A		HSFD + BAY 60-4552
	ND (n = 8)	HSFD (n = 11)	0.1 mg/kg/day (n = 6)	1.0 mg/kg/day (n = 10)	0.3 mg/kg/day (n = 9)	3.0 mg/kg/day (n = 10)
BW (g)	332 ± 3	315 ± 7	331 ± 16	338 ± 5	328 ± 6	345 ± 14
EDV (μL)	39 ± 16	330 ± 15	331 ± 29	332 ± 22	356 ± 21	379 ± 21
ESV (μL)	141 ± 10*	102 ± 7	110 ± 11	98 ± 10	111 ± 11	120 ± 9
EF (%)	65 ± 1	69 ± 1	67 ± 2	71 ± 1	69 ± 2	67 ± 1
SV (μL)	255 ± 9	229 ± 10	222 ± 19	234 ± 14	245 ± 14	259 ± 13
CO (mL/min)	89 ± 4	80 ± 4	76 ± 7	80 ± 5	86 ± 6	89 ± 6
LVM/BW (mg/g)	2.68 ± 0.03*	3.08 ± 0.06	2.69 ± 0.08*	2.82 ± 0.07*	3.06 ± 0.07	2.85 ± 0.10

Echocardiographic analysis was performed after 7 weeks of HSFD. Treatments were administered in chow starting 1 week after initiation of HSFD. All values are expressed as mean ± SEM. ND, normal diet; HSFD, high salt/fat diet; BW, body weight at week 7; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; SV, stroke volume; CO, cardiac output; LVM/BW, left ventricular mass to body weight ratio. Statistical comparisons were performed using one-way ANOVA analysis with a Dunnett’s post-test where *P < 0.05 vs. HSFD control SHR-SP.